Veracyte, a developer of genomic cancer tests including Decipher for prostate cancer and Afirma for thyroid cancer, has been rated Hold due to weakening growth prospects and a vanished valuation premium. The company now expects a 40% lower annual increase in Decipher test volumes compared to previous years. Despite trading below sector medians at 2.87x forward sales and 12.95x earnings, consensus forecasts a 19.38% decline in earnings per share by 2027. While Veracyte maintains strong cash flow and margins, its near-term growth heavily relies on Decipher and Afirma, with new product launches facing delays and reimbursement challenges.
Veracyte's stock is in limbo as it faces slowing test volume growth, with a 40% lower annual increase expected for its Decipher test. For readers following the health sector, here is Pluang's market snapshot as of Nov 12, 2026 22:11 WIB: out of 150 US health stocks, 42 rose and 108 fell. Notable movers include NVAX at USD 9.36 with a 6.26% decline and 83% sell order activity, RXRX at USD 3.37 with a 6.13% decline and 100% buy order activity, and CLPT at USD 8.61 with a 6.11% decline.
Existing-home sales in the U.S. dropped 5.5% month-over-month and 8.8% year-over-year in October, reaching the lowest level since August 2010. The decline is attributed to mortgage rates rising to their highest since 2000, making home buying more dif...
The global specialty zeolites market, valued at $1 million in 2025, is projected to reach $1.5 million by 2032 with a 5.8% CAGR. Growth is fueled by stricter environmental regulations and rising demand in water treatment, petrochemicals, agriculture,...
The global cell lysis and cell fractionation market, valued at $2.8 billion in 2025, is projected to grow to $4.5 billion by 2032 at a 7% CAGR. Growth is fueled by advances in biotechnology, increased life sciences research investments, and rising de...
atQor has been named a finalist for the 2026 Microsoft Partner of the Year Award in the Agents category, recognized for its innovative and scalable agentic AI solutions deployed across nine industries. The company developed 252 AI agents in FY26, wit...
Interlink Electronics announced a 3.4% revenue increase to $3.06 million for Q3 2026 and a 9.6% rise to $9.9 million for the first nine months of 2026, driven by higher shipments of force-sensing and gas-sensor products. The company reported a net lo...
